Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma

Next Previous
Trial Profile

A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sotatercept (Primary)
  • Indications Bone disorders; Multiple myeloma
  • Focus Biomarker; Therapeutic Use

Most Recent Events

  • 30 Aug 2016 Status changed from recruiting to withdrawn prior to enrolment.
  • 22 Feb 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov record.
  • 02 Oct 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top